Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10539725			
Filing Date		2005-06-20			
First Named Inventor	Ralf I	RESKI			
Art Unit		1651			
Examiner Name	Unkn	own			
Attorney Docket Numb	er	STURK0019			

				Attorn	ey Doc	ket Number	STURK0019				
					U.S.I	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Issue Date Name of Patentee or Applicant of cited Document			Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
-			U.S.P.	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		_
Examiner Cite Publication Number Kind Publication Codet Date		of cited Document Relev			s,Columns,Lines where ant Passages or Relevant es Appear						
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	id buttor	1. Add		_
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	nent Country Code ² i Rind Code ⁴ Publication Date Name of Patentee Applicant of cited Document		e or	where Rele	or Relevant	+			
	1	01/29242	wo		A2	2001-04-26	MONSANTO COI	MPANY			
			wo		A2	2001-04-12	Greenovation				_
	2	01/25456	WO		-						-
If you wis		01/25456 dd additional Foreign P		cument	citation	information pl	ease click the Ad	d button	Add		Ľ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Examiner Cite

Application Number		10539725
Filing Date		2005-06-20
First Named Inventor	Ratf I	RESKI
Art Unit		1651
Examiner Name	Unkn	own
Attorney Docket Numb	er	STURK0019

muais	INO	publisher, city and/or country where published.	
	1	RESKI et al.; Genome analysis of the moss Physicomitrella patiens (Hedw.) B.S.G.; Moi Gen Genet, 1994, vol. 244; pages 352-359.	
	2	ENGEL; THE INDUCTION OF BIOCHEMICAL AND MORPHOLOGICAL MUTANTS IN THE MOSS PHYSCOMITRELLA PATENS, Amer J. Bot, 1968; vol. 55(4); pages 438-446.	
	3	Topfer et al.; NAR 15; 1997; page 599; IRL Press Limited Oxford England.	
	4	RESKI et al.; induction of budding on chloronemata and cautionemata of the moss, Physicomitrella patiens, using isopentary/adenine; Planta; 1985; vol. 165; pages 354-358.	
	5	SCHAEFER: Principles and protocols for the moss Physocombrella patens; institute of Ecology, Laboratory of Plant Cell Genetics, University of Lausanne; May 2001; pages 1-14.	
	6	SCHAEFER et al., Stable transformation of the moss Physicomitrella patent; Mol Gen Genet; 1991; vol. 226; pages 418-424.	
	7	RESKI et al.; Production of a heterologous protein in bioreactor cultures of fully differentiated moss plants; Plant Tissue and Biotechnology; September 1996; vol. 2; No. 3; pages 142-147.	
	8	STREPP et al.; Plant nuclear gene knockout reveals a role in plastid division for the homolog of the bacterial cell division protein FisZ, an ancestral fublin; Proc. Natl. Acad. Sci. USA; April 1998; vol. 95; pages 4369-4373.	
	9	WILSON et al.: Analysis of Asn-linked glycans from vegetable foodstuffs: wiespread occurrence of Lew's a, core; Glycobiology; 2001; vol. 11; no. 4; pages 261-274.	
	10	KOPRIVOVA et al.; Functional Knockout of the Adenosine 5-Phosphosulfate Reductase Gene in Physoomitrella patiens Revives an Old Route of Sulfate Assimilation; The Journal of Boiological Chemistry, 2002, vol. 277, no. 35, pages 32195-32011.	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

	d additional non-patent literature document citation information please click the Add button Add	
14	International Search Report (PCT/ISA/210); PCT/EP2003/14576, completed May 25, 2004.	
13	LERCUGE et al.; N-Glycoprotein biosynthesis in plants: recent developments and future trends; 1998; vol. 38; pages 31-48.	
12	SCHAFER et al., Efficient gene targeting in the moss Physiconnitrella patients; The Plant Journal; 1997, vol. 11; no. 6; June 1997; pages 1195-1206.	
11	KIESSLING et al.; Visualization of a Cytoskeleton-like FlsZ Network in Chloroplasts; JCB Report, 2000, vol. 151, no. 4, pages 945-950.	

Examiner Signature | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant

1 See Kind Codes of USPTO Patient Documents at year LISETQ.GQU or MECP 901.64. ² Entire office that issued for document, by the hovelets code (WIPO Standard ST3.) ² For Jeapnese patient concurrent, be national or the year of the Empower must preced the series and number of the planta of countering the scale of the Indiana of the year of the Empower must precede the series illumber of the planta document. A find of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁹ Applicant is to place a check mark here if English Imaguage Praintations in attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10539725
Filing Date		2005-06-20
First Named Inventor	Ralf F	RESKI
Art Unit		1651
Examiner Name	Unkn	own
Attorney Docket Numb	er	STURK0019

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 98	to make	the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(a)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-03-31
Name/Print	Joera-Uwe Szipi	Registration Number	31799

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.